Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Xeris Biopharma Holdings, Inc. - Common Stock
(NQ:
XERS
)
10.19
+1.11 (+12.17%)
Delayed Quote
Updated: 3:15 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xeris Biopharma Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 02, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism
September 09, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Details for XP-8121 Program Overview Webinar
August 26, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris (XERS) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
Recorlev revenue surged 81% year-over-year, driving tightened full-year guidance to $385M–$390M.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Retirement
Xeris Biopharma (NASDAQ:XERS) Achieves First Profit, Beats Q1 Estimates with 95% Recorlev Surge
↗
May 07, 2026
Via
Chartmill
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges on Strong Q4 Earnings and Robust 2026 Outlook
↗
March 02, 2026
Via
Chartmill
Xeris Biopharma Q2 Earnings Call Highlights
↗
August 07, 2026
Xeris Biopharma (NASDAQ:XERS) reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of...
Via
MarketBeat
Topics
Earnings
Retirement
Xeris Biopharma Reports Second Quarter 2026 Financial Results
August 06, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
July 23, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 02, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Updates to Its Board of Directors
June 30, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®
June 11, 2026
From
Xeris Pharmaceuticals, Inc.
Via
Business Wire
Xeris Biopharma Announces Private Exchange of Convertible Notes
June 11, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Q1 Earnings Call Highlights
↗
May 09, 2026
Xeris Biopharma (NASDAQ:XERS) reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution...
Via
MarketBeat
Topics
Earnings
Xeris (XERS) Q1 2026 Earnings Call Transcript
↗
May 07, 2026
Xeris (XERS) Q1 2026 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Xeris Biopharma Reports First Quarter 2026 Financial Results
May 07, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
April 23, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 03, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
↗
March 02, 2026
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript
Via
The Motley Fool
Topics
Intellectual Property
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
March 02, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
February 26, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
February 17, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
January 08, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 02, 2026
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday
↗
December 31, 2025
One of the company's key drugs won't be challenged by a competing medication anytime soon.
Via
The Motley Fool
The market is filled with gapping stocks in Wednesday's session.
↗
December 31, 2025
Via
Chartmill
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
December 01, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript
↗
November 06, 2025
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript
Via
The Motley Fool
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates
↗
November 06, 2025
Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance.
Via
Chartmill
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
November 06, 2025
From
Xeris Biopharma Holdings, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
